A photoconverter, a skin external composition and uses thereof

Abstract

The present application provides a light converter, a skin external preparation, and use thereof. The light converter can improve the conversion efficiency of converting harmful light contained in incident light into beneficial light, thereby preventing and / or improving the damage of harmful light to the skin and maximizing the positive effect of sunlight on the skin.

Description

Technical Field

[0001] This application relates to the field of daily chemical technology, and in particular to a photoconverter, a topical skin composition, and its use. Background Technology

[0002] With the popularization of knowledge about photoaging, sun protection has become an essential step in consumers' skin care. Currently, there are two main types of sun protection technologies on the market: (1) using ultraviolet shielding agents or absorbers to filter out UVA and UVB in sunlight; (2) using a combination of UV and visible light shielding agents to block most wavelengths of sunlight from contacting the skin.

[0003] However, different wavelengths of sunlight have different effects on the skin. For example, ultraviolet light (UVB) with a wavelength of 280-320nm can cause DNA damage, inflammation, sunburn, photoaging, and skin cancer (DOI: 10.1046 / j.1523-1747.1998.00436.x), ultraviolet light (UVA) with a wavelength of 320-400nm can cause DNA damage, hyperpigmentation, and immunosuppression (DOI: 10.1067 / mjd.2001.112913), and visible light (VIS-1) with a wavelength of 400-550nm can cause free radical (ROS / RNS) or oxidative stress (DOI: 10.1111 / phpp.12111). Visible light with wavelengths of 550-760nm (VIS-2) promotes collagen production (DOI: 10.1089 / pho.2013.3616), visible light with a wavelength of 660nm can positively impact skin appearance by reducing the expression of metalloproteinase MMP-1 and upregulating collagen production (DOI: 10.1038 / jid.2009.186), and light with wavelengths of 570-810nm shows a positive effect on skin regeneration and increased intradermal collagen (DOI: 10.1089 / pho.2013.3616). This indicates that UVB, UVA, and VIS-1 are significantly harmful to the skin, while VIS-2 has benefits. Therefore, sunscreen technologies that indiscriminately block all wavelengths of sunlight from contacting the skin are unscientific.

[0004] Although existing technologies utilize photoconverting materials for scientific sun protection—which absorb harmful light and convert it into beneficial light greater than 550nm before re-emission—their photoconversion efficiency is too low to overcome the shortcomings of existing technologies. Summary of the Invention

[0005] In view of the above-mentioned problems, this application provides a light conversion agent that can improve the conversion efficiency of harmful light contained in incident light into beneficial light, thereby preventing and / or improving the damage of harmful light to the skin and maximizing the positive effects of sunlight on the skin.

[0006] The specific technical solution of this application is as follows:

[0007] 1. A photoconverter comprising lutein and lactoferrin, wherein the mass ratio of lutein to lactoferrin is 2-40:1.

[0008] 2. The light conversion agent according to item 1, wherein the light conversion agent further comprises a solvent, a stabilizer, and a preservative.

[0009] 3. A topical skin composition comprising the photoconverter described in claim 1 or 2.

[0010] 4. The composition according to item 3, wherein the lactoferrin is 0.0005%-1% and the lutein is 0.001%-1% by mass percentage in the composition.

[0011] 5. The composition according to item 3 or 4, wherein the composition further comprises a sunscreen agent, a skin care ingredient, and / or other photoconverter.

[0012] 6. Use of the light-converting agent described in item 1 or 2, or the composition described in any one of items 3-5, in absorbing harmful light and / or emitting beneficial light.

[0013] 7. The use as described in item 6, for preventing and / or improving the damage of harmful light to the skin and / or increasing the skin-care effects of beneficial light.

[0014] 8. Uses of lutein as a light conversion agent.

[0015] 9. Uses of lactoferrin as a photoconversion enhancer

[0016] 10. The use of the lactoferrin in improving the light conversion efficiency of lutein, according to the use described in item 9.

[0017] The effects of the invention

[0018] This application is the first to discover that lutein can convert harmful light contained in incident light into beneficial light.

[0019] Furthermore, this application demonstrates that by combining lutein and lactoferrin, the light conversion efficiency of lutein can be improved.

[0020] Furthermore, when lutein or its combination with lactoferrin is used in topical skin compositions, it can prevent and / or improve skin damage caused by harmful light and increase the skin-care effects of beneficial light. Attached Figure Description

[0021] Figure 1 This is a schematic diagram of the absorption curves of the compositions or monomers of the examples and comparative examples at different wavelengths.

[0022] Figure 2A This is a schematic diagram of the fluorescence emission curves of the compositions or monomers of the examples and comparative examples at an excitation wavelength of 410 nm.

[0023] Figure 2B This is a schematic diagram of the fluorescence emission curves of the compositions or monomers of the examples and comparative examples at an excitation wavelength of 450 nm.

[0024] Figure 2C This is a schematic diagram of the fluorescence emission curves of the compositions or monomers of the examples and comparative examples at an excitation wavelength of 490 nm. Detailed Implementation

[0025] The present application will now be described in detail with reference to the described embodiments. Although specific embodiments of the present application are shown, it should be understood that the present application can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this application will be thorough and complete, and will fully convey the scope of the present application to those skilled in the art.

[0026] It should be noted that certain terms are used in the specification and claims to refer to specific components. Those skilled in the art will understand that different terms may be used to refer to the same component. This specification and claims do not distinguish components based on differences in terminology, but rather on differences in function. The terms "comprising" or "including" used throughout the specification and claims are open-ended and should be interpreted as "comprising but not limited to." The following descriptions in the specification are preferred embodiments for carrying out this application; however, these descriptions are for the purpose of understanding the general principles of the specification and are not intended to limit the scope of this application. The scope of protection of this application shall be determined by the appended claims.

[0027] This application provides a light conversion agent comprising lutein and lactoferrin, wherein the mass ratio of lutein to lactoferrin is 2-40:1.

[0028] In this document, light conversion refers to the conversion of light of different wavelengths. In this application, light conversion refers to the conversion of harmful light contained in incident light into beneficial light, thereby preventing and / or improving the damage of harmful light to the skin and increasing the skin care effect of beneficial light.

[0029] Lutein, also known as carotenoids, carotene, plant lutein, riboflavin, marigold extract, and plant lutein, is generally found in leafy green vegetables.

[0030] Lactoferrin itself does not have a significant photoconversion effect. The inventors mixed lactoferrin with lutein, which can improve the photoconversion effect of lutein, thus achieving a synergistic effect.

[0031] In some embodiments of this application, the mass ratio of lutein to lactoferrin (n) 叶黄素 :n 乳铁蛋白 The possible ratios are 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, 40:1, etc.

[0032] In some embodiments of this application, the light conversion agent further includes a solvent. This solvent can be one commonly used in the art.

[0033] In some embodiments of this application, the solvent may be any solvent capable of dissolving the target component, including but not limited to organic solvents and inorganic solvents. In some specific embodiments, the organic solvent may include alcohols, and the inorganic solvent may include water.

[0034] In some embodiments of this application, the light conversion agent further includes a stabilizer. This can be a stabilizer commonly used in the art.

[0035] In some embodiments of this application, the stabilizer includes, for example, carbomer, bio-gum, acrylates and their modified forms, cellulose, etc.

[0036] In some embodiments of this application, the light conversion agent further includes a preservative. This can be a preservative commonly used in the art.

[0037] In some embodiments of this application, the preservatives include parabens, glycols, benzoic acids, phenoxyethanol, sorbic acid, etc.

[0038] The preparation method of the above-mentioned photoconverter is not particularly limited in this application, as long as lactoferrin and lutein are mixed evenly or dispersed evenly in a solvent.

[0039] In some embodiments of this application, lactoferrin and lutein are dissolved in a solvent, and then the two are mixed in the proportions described in this application.

[0040] In some embodiments of this application, ultrasonic treatment may be used to accelerate dissolution.

[0041] In some embodiments of this application, the method for preparing the photoconverter includes dissolving lactoferrin in water, adding lutein solid powder, and ultrasonically dispersing it evenly.

[0042] In some embodiments of this application, the ultrasonic conditions can be 10-60 kHz and 15-35 °C.

[0043] In some embodiments of this application, the method for preparing the photoconverter includes dissolving lactoferrin in water, dissolving lutein in ethanol, mixing the two evenly, and drying to obtain the final product.

[0044] Preferably, the pH of the lactoferrin aqueous solution is adjusted to alkaline, and then an ethanol solution of lutein is added. The alkalinity is, for example, pH 10-12. Further, the pH of the mixed solution is adjusted to 5-6.

[0045] In some specific embodiments of this application, the preparation method of the above-mentioned light conversion agent includes:

[0046] (1) Dissolve lactoferrin in water;

[0047] (2) Adjust the pH of the solution to 10.0-12.0;

[0048] (3) Dissolve lutein in ethanol;

[0049] (4) Add the ethanol solution of lutein to the lactoferrin aqueous solution obtained in step (1) and mix well;

[0050] (5) Adjust the pH of the mixed solution to 5.0-6.0;

[0051] (6) Dialyze to remove solvent and dry.

[0052] In some embodiments of this application, in step (6), the mixed solution is dialyzed in a buffer solution, preferably an aqueous solution of 3-(N-morpholino)ethanesulfonic acid, preferably with a pH of 6.0 ± 0.5.

[0053] In some embodiments of this application, the dialysis time in step (6) is 6-24 hours.

[0054] In some embodiments of this application, in step (6), the molecular weight cutoff of the dialysis bag is 800-1000 Da.

[0055] In some specific embodiments of this application, the photoconverter is prepared by the following method: lactoferrin is dissolved in water, and the pH is adjusted to 10.0-12.0. After standing at room temperature for 10-40 min, an ethanol solution of lutein is added. Under ice bath conditions, the mixture is stirred thoroughly until homogeneous. The pH of the mixed solution is adjusted to 5.0-6.0, and the mixed solution is dialyzed in a buffer solution for 6-24 h to remove the solvent, and then dried and stored.

[0056] This application also provides a topical skin composition comprising the above-mentioned photoconverter.

[0057] In some embodiments, the lactoferrin is 0.0005%-1% and the lutein is 0.001%-1% by mass in the composition.

[0058] For example, the lactoferrin, by mass percentage in the composition, is 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.002%, 0.003%, 0.004%, 0.05%, 0.006%, 0.007%, 0.008%, 0.009%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, etc.

[0059] The lutein is present in the following concentrations: 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.002%, 0.003%, 0.004%, 0.05%, 0.006%, 0.007%, 0.008%, 0.009%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, etc.

[0060] In some embodiments, the composition further comprises sunscreens, skin care ingredients, and / or other light-converting agents.

[0061] In this application, no restrictions are placed on sunscreens, skin care ingredients, and other light-converting agents, which may be commonly used sunscreens, skin care ingredients, and light-converting agents in the art.

[0062] For example, the sunscreen agent can be any type of sunscreen agent known in the art, as long as it has a sun protection effect; for example, it can be a physical sunscreen agent, a chemical sunscreen agent, or a combination thereof. Furthermore, one or more of these sunscreen agents can be used.

[0063] In this application, physical sunscreen agents may be selected from titanium dioxide, zinc oxide, etc.;

[0064] Chemical sunscreens can be selected from octocrylene, methylene bis-benzotriazolyl tetramethylbutylphenol, ethylhexyl methoxycinnamate, ethylhexyl salicylate, ethylhexyl triazine ketone, bis-ethylhexyloxyphenol methoxyphenyl triazine, etc.

[0065] In this application, the skin care ingredients can be any skin care ingredients known in the art, such as skin care ingredients with moisturizing, skin care, and anti-inflammatory effects. In addition, one or more of these skin care ingredients can be used.

[0066] In this application, other photoconverters can be any photoconverters known in the art, such as including but not limited to emodin, aloe-emodin, rhein, emodin methyl ether, rhein, chrysophanol, emodin glucoside, aloe-emodin glucoside, chrysophanol glucoside, alizarin, hydroxyalizarin, pseudohydroxyalizarin, etc. Furthermore, one or more of these photoconverters can be used.

[0067] The preparation of the above-mentioned topical skin composition is not particularly limited in this application, and it can be prepared into various dosage forms such as emulsion, cream, and powder as needed.

[0068] This application provides the use of the above-described composition in absorbing harmful light and / or emitting beneficial light.

[0069] The composition described in this application can absorb harmful light and emit beneficial light, thus it can be used as a topical skin composition.

[0070] In some implementations, it is used to prevent and / or improve the damage of harmful light to the skin and / or increase the skin-care effects of beneficial light.

[0071] In this application, no restrictions are placed on the specific type of damage to the skin caused by harmful light. It can be any type of skin damage caused by harmful light, such as skin injury or skin aging.

[0072] In this application, no restrictions are placed on the specific type of skin care effect of beneficial light on the skin, as long as it can have a skin care effect, such as reducing the expression of metalloproteinase MMP-1, promoting collagen production, and skin regeneration.

[0073] In some embodiments, the harmful light includes ultraviolet light with a wavelength of 280-400 nm and / or visible light with a wavelength of 400-550 nm. In some embodiments, the beneficial light includes visible light with a wavelength of 550-760 nm.

[0074] This application provides the use of lutein as a light conversion agent.

[0075] The inventors discovered for the first time that lutein can be used as a light conversion agent, that is, it can convert harmful light contained in incident light into beneficial light.

[0076] This application provides the use of lactoferrin as a photoconversion enhancer.

[0077] Preferably, the use of lactoferrin in improving the light conversion efficiency of lutein.

[0078] This application, by mixing lactoferrin with lutein, can greatly improve the light conversion effect of lutein, thereby achieving a synergistic effect.

[0079] This application provides the use of a combination of lutein and lactoferrin as a photoconverter, preferably wherein the mass ratio of lutein to lactoferrin is 2-40:1.

[0080] The mass ratio of lutein to lactoferrin (n) 叶黄素 :n 乳铁蛋白 The possible ratios are 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1, 37:1, 38:1, 39:1, 40:1, etc.

[0081] Example

[0082] This application provides a general and / or specific description of the materials and experimental methods used in the experiments. In the following examples, unless otherwise specified, % represents wt%, i.e., weight percentage. Reagents or instruments used, unless otherwise specified, are all commercially available conventional reagent products. The raw materials used in the examples are shown in Table 1, and the experimental equipment used is shown in Table 2.

[0083] Table 1

[0084] Raw material name Supplier, batch number, and other information Lutein Aladdin lactoferrin Wuhan Heyuan Biotechnology Co., Ltd. Lot No. 20230130 beta-carotene Aladdin Sodium hydroxide Aladdin hydrochloric acid Aladdin

[0085] Table 2

[0086]

[0087]

[0088] Experiment 1: Measurement of absorption and emission curves

[0089] 1. Methods for determining absorption curves

[0090] Lactoferrin was dissolved in water, keeping the solution clear and transparent. Lutein solid powder was added and the solution was dispersed evenly under ultrasonic conditions at 40 kHz and 25 °C. 300 μl of the solution was pipetted into a cuvette, and the absorbance curve was measured using a UV-Vis absorption spectrometer. The results are as follows: Figure 1 As shown in Table 3.

[0091] Table 3

[0092] Lutein (mg / ml) Lactoferrin (mg / ml) Lutein: Lactoferrin Test Example 1 / 1 / Test Example 2 0.98 0.02 49：1 Test Example 3 0.5 0.5 1：1 Test Example 4 1 / / Test Example 5 0.975 0.025 39：1 Test Example 6 0.667 0.333 2：1 Test Example 7 0.4875 0.0125 39：1

[0093] Depend on Figure 1 It can be seen that the substances in different test cases all have absorption spectra in the visible light (VIS-1) region with wavelengths of 400-550nm.

[0094] 2. Methods for determining emission curves

[0095] 2-1 Sample Preparation

[0096] Preparation of Sample 1

[0097] Dissolve 2 mg of lactoferrin in 90 ml of water, keeping the solution clear and transparent. Adjust the pH to 11.4 with 1 mol / L NaOH. After standing at room temperature for 30 min, dissolve 98 mg of lutein in 10 ml of ethanol and add it to the aqueous phase. Stir thoroughly under ice bath conditions until the two are thoroughly mixed. Adjust the pH of the mixed solution to 6.0 with 1 mol / L hydrochloric acid. Dialyze the above solution in an aqueous solution of 3-(N-morpholino)ethanesulfonic acid at pH 6.0 for 12 h. The molecular weight cutoff of the dialysis bag is 800-1000 Da. Remove the solvent, dry and store to obtain sample 1.

[0098] Preparation of Sample 2

[0099] Dissolve 50 mg of lactoferrin in 90 ml of water, keeping the solution clear and transparent. Adjust the pH to 11.4 with 1 mol / L NaOH. After standing at room temperature for 30 min, dissolve 50 mg of lutein in 10 ml of ethanol and add it to the aqueous phase. Stir thoroughly under ice bath conditions until the two are thoroughly mixed. Adjust the pH of the mixed solution to 6.0 with 1 mol / L hydrochloric acid. Dialyze the above solution in an aqueous solution of 3-(N-morpholino)ethanesulfonic acid at pH 6.0 for 12 h. The molecular weight cutoff of the dialysis bag is 800-1000 Da. Remove the solvent, dry and store the solution to obtain sample 2.

[0100] Preparation of Sample 3

[0101] Dissolve 2.5 mg of lactoferrin in 90 ml of water, keeping the solution clear and transparent. Adjust the pH to 11.4 with 1 mol / L NaOH. After standing at room temperature for 30 min, dissolve 97.5 mg of lutein in 10 ml of ethanol and add it to the aqueous phase. Stir thoroughly under ice bath conditions until the mixture is homogeneous. Adjust the pH of the mixed solution to 6.0 with 1 mol / L hydrochloric acid. Dialyze the above solution in an aqueous solution of 3-(N-morpholino)ethanesulfonic acid at pH 6.0 for 12 h. The molecular weight cutoff of the dialysis bag is 800-1000 Da. Remove the solvent, dry and store the solution to obtain sample 3.

[0102] Preparation of Sample 4

[0103] Dissolve 33.3 mg of lactoferrin in 90 ml of water, keeping the solution clear and transparent. Adjust the pH to 11.4 with 1 mol / L NaOH. After standing at room temperature for 30 min, dissolve 66.7 mg of lutein in 10 ml of ethanol and add it to the aqueous phase. Stir thoroughly under ice bath conditions until the two are thoroughly mixed. Adjust the pH of the mixed solution to 6.0 with 1 mol / L hydrochloric acid. Dialyze the above solution in an aqueous solution of 3-(N-morpholino)ethanesulfonic acid at pH 6.0 for 12 h. The molecular weight cutoff of the dialysis bag is 800-1000 Da. Remove the solvent, dry and store the solution to obtain sample 4.

[0104] Preparation of Sample 5

[0105] Dissolve 10 mg of lactoferrin in 90 ml of water, keeping the solution clear and transparent. Adjust the pH to 11.4 with 1 mol / L NaOH. After standing at room temperature for 30 min, dissolve 90 mg of lutein in 10 ml of ethanol and add it to the aqueous phase. Stir thoroughly under ice bath conditions until the two are thoroughly mixed. Adjust the pH of the mixed solution to 6.0 with 1 mol / L hydrochloric acid. Dialyze the above solution in an aqueous solution of 3-(N-morpholino)ethanesulfonic acid at pH 6.0 for 12 h. The molecular weight cutoff of the dialysis bag is 800-1000 Da. Remove the solvent, dry and store the solution to obtain sample 5.

[0106] The mass of lutein and lactoferrin in samples 1-5 is shown in Table 4 below.

[0107] Table 4

[0108] Lutein: Lactoferrin Sample 1 49：1 Sample 2 1：1 Sample 3 39：1 Sample 4 2：1 Sample 5 9：1

[0109] 2-2 Emission Curve Measurement

[0110] Test Case A

[0111] β-carotene was added to water and dispersed evenly under ultrasonic conditions at 40 kHz and 25 °C. The content of the components is shown in Table 5. 300 μl of the above solution was pipetted into a cuvette, and the emission curve was measured using a fluorescence spectrometer.

[0112] Test Case B

[0113] Lactoferrin was dissolved in water, keeping the solution clear and transparent. The composition of the solution is shown in Table 5. 300 μl of the solution was pipetted into a cuvette, and the emission curve was measured using a fluorescence spectrometer.

[0114] Test Case C

[0115] Lutein solid powder was added to water and dispersed evenly under ultrasonic conditions at 40 kHz and 25 °C. The content of the components is shown in Table 5. 300 μl of the above solution was taken into a cuvette using a pipette, and the emission curve was measured using a fluorescence spectrometer.

[0116] Test Case DI

[0117] Samples 1-5 were dissolved in water, and the content of the components is shown in Table 5. 300 μl of each solution was taken into a cuvette using a pipette, and the emission curves were measured using a fluorescence spectrometer.

[0118] Test case JK

[0119] Lactoferrin was dissolved in water, keeping it clear and transparent. Lutein solid powder was added and dispersed evenly under ultrasonic conditions at 40 kHz and 25 °C. The composition is shown in Table 5. 300 μl of the solution was pipetted into a cuvette, and the emission curve was measured using a fluorescence spectrometer.

[0120] 2-3 Results Analysis

[0121] The results are shown in Table 6 and Figures 2A to 2C As shown, Table 2A shows the fluorescence emission curves under 410 nm excitation light. Figure 2B The fluorescence emission curve is under 450nm excitation light. Figure 2C The fluorescence emission curve is under 490nm excitation light.

[0122] Table 5

[0123]

[0124]

[0125] Table 6

[0126]

[0127] As shown in Table 6 and Figures 2 (A, B, C), a comparison between test example C and test example A reveals that lutein exhibits better light conversion, converting harmful light contained in incident light into beneficial light. Test example B shows that lactoferrin has a weaker light conversion effect.

[0128] The comparison between test case C and test case FK shows that the addition of lactoferrin can further improve the light conversion efficiency of lutein and produce a synergistic effect.

[0129] Application examples

[0130] Application Example 1: Lotion-textured sunscreen products

[0131] This formula can be used to prepare sunscreen products with a lotion-like texture, such as sunscreen creams, sunscreen serums, and sunscreen gels.

[0132] Weigh 0.25g of disodium EDTA, 3.00g of glycerol and 0.20g of cross-linked acrylate / C10-30 alkanol acrylate and dissolve them in 67.01g of water. Add 2.00g of sodium cetearyl sulfate, heat to 70-80℃ to melt, and stir until homogeneous to obtain the aqueous phase.

[0133] Weigh 6.00g of caprylic / capric triglyceride, 7.50g of butyl methoxydibenzoylmethane, 7.00g of octocrylene, and 4g of titanium dioxide. Mix with the aqueous phase and homogenize for 3 minutes. Then, cool to 45°C and add 1g of polyurethane-35, 2g of the composition of sample 3, and 0.04g of citric acid in sequence. Stir until homogeneous to the desired state.

[0134] Application Example 2: Cream-textured sunscreen products

[0135] This formula can be used to prepare sunscreen products with a cream or lotion texture, such as sunscreen sticks.

[0136] Weigh 29.00 g of diisostearyl malate, 27.60 g of polyisobutylene, 5.00 g of dodecyl octanol, 4.90 g of glyceryl stearate, 5.00 g of VP / hexadecene copolymer, and 5.00 g of beeswax. Heat to 85 degrees Celsius until fully melted, then stir until homogeneous. After cooling to 65 degrees Celsius, add 4.00 g of caprylic / capric triglyceride, 7.50 g of butyl methoxydibenzoylmethane, 7.00 g of octocrylene, and 4 g of titanium dioxide. Stir for 5 minutes until homogeneous. Add 1 g of the composition from sample 3 and cool to room temperature.

[0137] Application Example 3: Powder-textured sunscreen products

[0138] This formula can be used to prepare powder-based sunscreen products such as liquid foundation, pressed powder, loose powder, and CC powder.

[0139] Weigh out 76.1g of talc, 16.8g of mica, 0.1g of ferrous oxide, 3g of titanium dioxide, 3g of zinc oxide and 1g of the composition of sample 3 in sequence, add them to a fixed volume Henschel mixer, and stir at a low speed of 100-300 RPM until fully mixed.

[0140] The above description is merely a preferred embodiment of this application and is not intended to limit the application in any other way. Any person skilled in the art may make changes or modifications to the disclosed technical content to create equivalent embodiments. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of this application without departing from the scope of the technical solution of this application shall still fall within the protection scope of this application.

Claims

1. A topical skin composition comprising a photoconverter, said photoconverter comprising lutein and lactoferrin, said lutein and lactoferrin having a mass ratio of 2-40:

1.

2. The topical skin composition according to claim 1, wherein the photoconverter further comprises a solvent, a stabilizer, and a preservative.

3. The composition according to claim 1, wherein the lactoferrin is 0.0005%-1% and the lutein is 0.001%-1% by mass percentage in the composition.

4. The composition according to any one of claims 1-3, wherein the composition further comprises a sunscreen, a skin care ingredient, and / or other photoconverter.

5. Use of the composition of any one of claims 1-4 in the preparation of a daily chemical product that absorbs harmful light and / or emits beneficial light.

6. The use according to claim 5, for preventing and / or improving the damage of harmful light to the skin and / or increasing the skin-care effect of beneficial light.

7. The use of lactoferrin as a light conversion enhancer in improving the light conversion efficiency of lutein, wherein the mass ratio of lutein to lactoferrin is 2-40:1.

Images